New evidence is emerging daily that COVID-19 isn’t just a respiratory disease; it is a blood disease. Data are emerging that COVID-19 infection can result in coagulopathy in severely ill patients, and there are reports of an increased risk of clinical and subclinical thrombosis in the setting of severe COVID-19 disease with multiple reports citing an increased incidence of thrombosis, especially venous thromboembolism.
The rapid onslaught of cases, the severity of critical illness and complications, and the desire to do something have resulted in a significant debate about the appropriate anticoagulant approach to preventing both macrovascular and microvascular thrombosis at a time when no data are available to inform decisions and guide clinical care.
The webinar presents crucial controversies in this area, using a case-based format to highlight these issues and discuss the known data and pros and cons of empiric treatments.
After the webinar, participants will be able to: • Debate the optimal intensity of anticoagulation for thromboprophylaxis in COVID-19 patients admitted to the wards. • Debate the optimal intensity of anticoagulation for thromboprophylaxis in COVID-19 patients admitted to the ICU. • Discuss the potential pros and cons of post-discharge thromboprophylaxis in COVID-19 patients.
Moderator: Jean Connors, MD (Brigham and Women's Hospital)
Lisa M. Baumann Kreuziger, MD, MS (Versiti, Medical College of Wisconsin)